Peyronie’s Disease Definition
“Peyronie’s Disease” received its name in 1743 after Louis XV’s personal physician, Francois Gigot de la Peyronie (the doctor himself, Peyronie had the disease) published a paper describing it.
What was the initial definition of Peyronie’s Disease? It was described by Peyronies as a disorder marked by induration of the corpora cavern of the penis, which urologists refer to today as penile curvature in the shaft in which scar tissue (or plaque has formed). The plaque pulls on the surrounding tissue and causes the penis to curve, often during an erection. A loss of length and girth may occur.
After over 600 years of healthcare innovation, only the disease’s symptoms (penile curvature and related effects) have been addressed, and the disease’s underlying epidemiology remains an enigma, with no one able to explain the origin of all cases.
Until now, fast-forward to 2023
The Peyronie’s Disease Breakthrough Urologist
After twenty years of intensive research and development, scientists and physicians at Morganstern Health deciphered the cause of Peyronie’s Disease and developed the world’s first clinically-proven non-surgical treatment solution for permanently removing the fibrous tissue plaques that cause all of its terrible symptoms.
This ground-breaking innovation, branded ExoSurge®, is presently available exclusively through Morganstern Health in Atlanta, Georgia.
When a disease remains incurable for centuries, its symptoms become the definition of the disease. Similarly, the efficacy of the treatments employed to treat the disease is measured by how well they alleviate its symptoms.
This human phenomenon is exemplified by the common cold. Coughing, sneezing, and congestion some of the most common symptoms of a cold, and people frequently assume we have a cold if we display these symptoms. Nobody inquiries about the type of virus we are fighting, such as rhinovirus, coronavirus, adenovirus, or enterovirus.
Since Peyronie’s Disease has remained similarly incurable, it has likewise become only known for its symptoms, even among many physicians, with erect curvature being the most notable definition.
Peyronie’s Symptoms
What are the common symptoms of Peyronie’s Disease?
The main symptom or sign of Peyronie’s is a bend or curve in the penis. Other symptoms such as difficulty or pain when having erections and difficulty having sexual intercourse may result.
7 Common Signs or Symptoms
- Penile curvature
- Reduced penile length (shortening)
- Loss of penile width which can resemble an hourglass shape
- Presence of scar tissue or plaque
- Pain during erections or otherwise
- Difficulty maintaining erections
- Pain during intercourse
Treatment that Cures Condition
This is what makes Morganstern’s new ExoSurge® technology completely different from anything ever used to treat Peyronie’s. ExoSurge® technology is a treatment that heals and cures the underlying disease of Peyronie’s, not just its symptoms. It is the latest advance as of 2023.
Morganstern’s ExoSurge® is the world’s first clinically-proven treatment to conservatively and permanently remove plaques and fibrosis associated with a Peyronie’s Disease diagnosis.
Who is Morganstern Health?
Morganstern Urology Clinic started treating patients in 1979 and has been repeatedly acknowledged for its outstanding patient care.
Steven L. Morganstern, MD is a recognized innovator in breakthrough therapeutics for treating erectile dysfunction, prostate cancer, men’s health, and cosmetic penile enhancement.
However, for the past twenty years his focus has been developing a curative solution for Peyronie’s Disease. Most of the first decade of his journey was isolating and identifying the underlying epidemiology of the disease, followed by years of trial and error with corrective treatments to cure the disease.
While we have more development work to do in terms of improving the speed of outcomes with complex cases, we’re now at 100% efficacy in terms of plaque reduction using baseline and follow up duplex Doppler sonographic testing as verifiable proof.
Georgia’s Longest Running Urology Clinic
After almost forty-five years of treating patients, Morganstern Medical is the longest running urologic platform in the state of Georgia, and one of the oldest in the US.
Our state-of-the-art 12,000 square foot clinic located in the heart of Buckhead in Atlanta, GA is dedicated to male sexual health challenges, including:
- Peyronie’s Disease
- Erectile Dysfunction
- Low-Testosterone / Hormone Deficiency
- Low Libido
- Micro Penile Syndrome
- Premature Ejaculation
- Penis Augmentation Surgeries
- Impotence
- Loss of Energy
- Nutritional Therapy
Largest Selection of Proprietary Treatments
Treatment protocols available exclusively at Morganstern Health, include:- Exclusive 15 Point Male Sexual Health Analysis
- Erectile Dysfunction (Patented)
- ExoSurge Peyronie’s Treatments (Patented)
- Low-Intensity Shockwave Treatments (Patented)
- External Counter pulsation Therapy for Penile Vascular Health (Patented)
- BioTE Hormone Pellet therapy
- Intracavernosal Penile Injection Therapy
- Non-surgical Penile Enlargement Procedures
- Penile Augmentation Surgery
Morganstern: Award-Winning
Our Morganstern Health clinic was recognized as “Best of Atlanta” for Urology Physicians by Atlanta awards group for ten consecutive years.
We’ve been included as one of the “Three Best Rated” urologists in Atlanta from “Best Businesses of 2019, 2018, 2017, 2016”.
Healthgrades recognized Dr. Morganstern as one of their elite Honor Roll Recognized Physicians in 2014 and 2015.
Morganstern Health: Recognized Innovators
Morganstern Health is America’s longest running men’s sexual health clinic. We’re renowned for innovative “firsts” within urology and men’s health, including:
“The only private clinic in the world chosen to be included for the original Viagra® trials”
“One of the very first urologists to innovate radioactive seeding for prostate cancer”
“First urologist in the United States to employ the use of low intensity shockwave therapy to treat patients with erectile dysfunction”
“Among the very first urologists to introduce penile prosthetic implants to resolve severe erectile dysfunction in the world”
“First non-university urologist to launch bioidentical pellets for testosterone therapy”
“First urologist in the world to provide cosmetic penile enhancements”
“Invented a breakthrough curative technology to permanently remove penile fibrosis and plaques associated with Peyronie’s Disease.”
“First urologist in the USA to invent a non-surgical solution for inadequate arterial blood flow to the penis.”
“Invented a breakthrough curative technology to permanently remove penile fibrosis and plaques associated with Peyronie’s disease”
“First urologist in the USA to invent a non-surgical solution for inadequate arterial blood flow to the penis”
What do ExoSurge® patients say about our Dr. Morganstern’s breakthrough new Peyronie’s technology?
The Morganstern ExoSurge Breakthrough
Many people, including lots of doctors would answer this question by saying: “reduce erect penile curvature”. But Peyronie’s disease is not defined by a curve. In fact, over 30% of patients with a Peyronie’s diagnosis have little or no curvature, but they still suffer from the build up of penile fibrosis and plaques in the soft tissue of the penis and the many negative side effects associated with that condition.We believe the improved clinical definition for Peyronie’s should be:
Peyronie’s Disease Redefined
Peyronie’s Disease (PD) is an acquired inflammatory condition characterized by the buildup of fibrous tissue plaques within the soft tissue of the penis and/or thickening of the tunica albuginea. In select cases, it’s triggered by a wound healing disorder.
Thus, a successful Peyronie’s Disease treatment is one that measurably and permanently removes Peyronie’s fibrous tissue plaques and reduces the size of an enlarged tunica (if applicable).
Thickening of the tunica albiquea is common with well- established Peyronies cases. Thickening can be defined both in terms of increased size from a form of swelling plus more pronounced tunica density.
Removal of Peyronie’s fibrosis is complex since the size and nature of established plaques as well as existing patient health dynamics all play important roles with the exact protocol to permanently remove the penile fibrous tissue plaques.
At the onset, the plaques, fibrosis, and scar tissue that cause all Peyronie’s symptoms can be precisely measured. Improvement can also be precisely quantified.
Uniquely compared to conditions like erectile dysfunction, the locations and sizes of Peyronie’s fibrosis and penile plaques can be quantifiably measured, in mm3, by dynamic penile color Doppler sonography (readily available at most urology clinics) after administration of intracavernosal alprostadil 10 mcg. To calculate the volume of the penile plaque, plaques are measured in three dimensions and using an ellipsoid formula: V =_ _length × _width × _thickness × _0:52 which is typically used in the evaluation other urogenital diseases.
Thus, 99% of existing Peyronie’s plaques, fibrosis and scar tissue can be fully quantified at the onset before any treatments begin and subsequently be reevaluated for signs of improvement through follow up sonography compared to the baseline to accurately determine if any therapeutic is eliminating Peyronie’s plaque.
Because there has never been a unified standard for defining a successful Peyronie’s treatment, existing Peyronie’s treatment devices and drug treatment approved by the FDA refer to clinical trials that measured success by the degree of change in erect curvature, which is only a potential symptom of Peyronie’s disease and proves nothing about healing the underlying cause of the curvature.
With all of this in mind, we believe it is critical to be as clear as we can about our use of statistics and to help clinicians and patients build appropriate expectations. Thus, we believe the revised gold standard for measuring improvement in regard to any Peyronie’s treatment technology should include an initial duplex ultrasonography that both measures the size of any and all penile plaques and records their location within the soft tissue of the penis.
In our soon to be published clinical study of Peyronie’s patients who completely treatment with ExoSurge IPG we saw a 79% reduction in fibrous tissue plaques (including cases with calcification) and a 60% reduction in measurable erect curvature (if applicable)
